丹参酮ⅡA对心血管系统的药理作用及剂型研究进展

doi:10.3969/j.issn.2095-1396.2016.04.004

神经药理学报 ›› 2016, Vol. 6 ›› Issue (4): 24-30.DOI: 10.3969/j.issn.2095-1396.2016.04.004

丹参酮ⅡA对心血管系统的药理作用及剂型研究进展

侯文书，张力

河北北方学院药学系，张家口，075000，中国

出版日期:2016-08-26 发布日期:2016-08-31
通讯作者: 张力，男，教授，硕士生导师；研究方向：神经药理学；Tel：+86-0313-4029188，E-mail：hbnulzhang@126.com
作者简介:侯文书，女，硕士研究生；研究方向：神经药理学；E-mail：houws0506@163.com
基金资助:
国家自然基金项目（No.81202192），河北省中医药管理局项目（No.2013075），河北省卫生厅项目（No.20130034）

Research Progress on Pharmacological Action and Dosage Form of Tanshinone II A on Cardiovascular System

HOU Wen-shu，ZHANG Li

The Department of Pharmacy，Hebei North University， Zhangjiakou，075000，China

Online:2016-08-26 Published:2016-08-31
Contact: 张力，男，教授，硕士生导师；研究方向：神经药理学；Tel：+86-0313-4029188，E-mail：hbnulzhang@126.com
About author:侯文书，女，硕士研究生；研究方向：神经药理学；E-mail：houws0506@163.com
Supported by:
国家自然基金项目（No.81202192），河北省中医药管理局项目（No.2013075），河北省卫生厅项目（No.20130034）

摘要/Abstract

摘要： 丹参酮Ⅱ A 是从唇形科植物丹参中提取出来的一种重要的脂溶性提取物，也是最有效的药理活性成分之一。许多实验和临床研究都表明，丹参酮Ⅱ A 可以预防或减缓多种疾病的进展，包括心血管疾病、癌症、新生儿缺氧缺血性脑病、肝纤维化和神经退行性疾病。而随着人口老龄化的发展，心血管疾病已成为威胁人类健康的
常见病，居各种死因首位。丹参酮Ⅱ A 对多种心血管疾病都有一定的保护作用，如：抗动脉粥样硬化、抗心肌缺血、抗心律失常、修复血管内皮细胞、改善冠状动脉血液循环、抗心肌肥厚等，然而丹参酮Ⅱ A 为脂溶性成分，有口服吸收差，生物利用度低的缺点，为改善丹参酮Ⅱ A 的现状，需要制备丹参酮Ⅱ A 新剂型，主要有注射用微乳、微丸、固体分散体、脂质体、纳米粒等。因此该文归纳总结国内外丹参酮Ⅱ A 研究现状。新剂型的开发使丹参酮Ⅱ A 在治疗心血管疾病发挥更大的药用价值，为进一步研究提供理论指导。

关键词: 丹参酮Ⅱ A , 心血管疾病, 剂型

Abstract: Tanshinone Ⅱ A is not only a kind of important fat-soluble extract which comes from Labiatae Salvia miltiorrhiza but also a kind of the most effective pharmacological active ingredients. So many experiments and clinical studies have shown that tanshinone Ⅱ A can prevent or attenuate the progress of multiple diseases including cardiovascular disease，cancer，neonatal hypoxic ischemic encephalopathy，liver fibrosis and neurodegenerative disease. With aging of population’s development，cardiovascular disease has become a common disease which threatens human health ranking fi rst of all causes of death. Tanshinone Ⅱ A has the effects of anti-atherosclerosis，anti-myocardial ischemia，anti-arrhythmic，repair of vascular endothelial cells and improvement of coronary blood circulation in cardiovascular system，however，tanshinone Ⅱ A is a fat-soluble component with the disadvantages of poor oral absorption and low bioavailability. Therefore，in order to improve the present situation of tanshinone Ⅱ A ，new dosage forms of tanshinone Ⅱ A should be prepared，such as injectable microemulsions，micro pill，solid dispersions，liposomes，nanoparticles，etc. Therefore，this article summarizes the domestic and international research situation. The results showed the development of new dosage forms made tanshinone Ⅱ A play a greater medical value in the treatment of cardiovascular diseases，providing theoretical guidance for further research.

Key words: tanshinone Ⅱ A , cardiovascular disease, dosage form

侯文书，张力. 丹参酮ⅡA对心血管系统的药理作用及剂型研究进展[J]. 神经药理学报, 2016, 6(4): 24-30.

HOU Wen-shu，ZHANG Li. Research Progress on Pharmacological Action and Dosage Form of Tanshinone II A on Cardiovascular System[J]. Acta Neuropharmacologica, 2016, 6(4): 24-30.

参考文献

[1] 国家药典委员会. 中华人民共和国药典[M]. 一部. 北京: 中国医药科技出版社，2015: 76-77.

[2] Chen Yi-le, Duan Geng-li, Xie Mei-fen, et al. Infrared-assisted extraction coupled with high-performance liquid chromatography for simultaneous determination of eight active compounds in radix salviae miltiorrhizae[J]. J Sep Sci, 2010, 33(17-18): 2888-2897.

[3] Li Xin, Du Jun-rong, Yu Yan, et al. Tanshinone IIA inhibits smooth muscle proliferation and intimal hyperplasia in the rat carotid balloon-injured model through inhibition of MAPK signaling pathway[J]. J Ethnopharmacol, 2010, 129(2): 273-279.

[4] Tang Fu-tian, Cao Yuan, Wang Tie-qiao, et al. Tanshinone IIA attenuates atherosclerosis in ApoE-/- mice through down-regulation of scavenger receptor expression[J]. Eur J Pharmacol, 2011, 650(1): 275-284.

[5] Fang Zhi-yuan, Lin Rong, Yuan Bing-xiang, et al. Tanshinone IIA inhibits atherosclerotic plaque formation by down-regulating MMP-2 and MMP-9 expression in rabbits fed a high-fat diet[J]. Life Sci, 2007, 81(17-18): 1339-1345.

[6] Xu Suo-wen, Peter J Little, Lan Tian, et al. Tanshinone IIA attenuates and stabilizes atherosclerotic plaques in Apolipoprotein-E knockout mice fed a high cholesterol diet[J]. Arch Biochem Biophys, 2011, 515(1/2): 72-79.

[7] Yang Jin-xiu, Pan Yan-yun, Ge Jun-hua, et al. Tanshinone IIA attenuates TNF-α-induced expression of VCAM-1 and ICAM-1 in endothelial progenitor cells by blocking activation of NF-κB[J]. Cell Physiol Biochem, 2016, 40(1-2): 195-206.

[8] Chang Cheng-chieh, Chu Chen-fu, Wang Chao-nin. The anti-atherosclerotic effect of tanshinone IIA is associated with the inhibition of TNF-α-induced VCAM-1, ICAM-1 and CX3CL1 expression[J]. Phytomedicine, 2014, 21(3): 207-216.

[9] Li Wei, Sun Wei, Yang Chuan-hua, et al. Tanshinone IIA protects against lipopolysaccharides-induced endothelial cell injury via Rho/Rho kinase pathway[J]. Chin J Integr Med, 2014, 20(3): 216-223.

[10] Zhou Wen-jing, Gui Qi-feng, Wu Yue, et al. Tanshinone IIA protects against methylglyoxal-induced injury in human brain microvascular endothelial cells[J]. Int J Clin Exp Med, 2015, 8(2): 1985-1992.

[11] Liu Xin, Guo Chun-yu, Ma Xiao-juan, et al. GW25-e1111 Anti-inflammatory effects of tanshinone IIA on oxidative-injured vascular endothelial cells are mediated by estrogen receptor activation and through ERK signaling pathway[J]. Cardiovasc Res, 2014, 1(16): c37-c38.

[12] Teng Yao-hong, Lu De-zhao, Fan Chun-lei, et al. Proteomic study on the protective effect of tanshinone IIA against oxidative injury to human umbilical vein endothelial cells by hydrogen peroxide[J]. Curr Proteomics, 2016, 10(4): 312-321.

[13] Tzu-huring Cheng, Hong-Jye Hong, Paul Chan. 90 Tanshinone IIA attenuates doxorubicin-induced injury in human umbilical vein endothelial cells[J]. J Hum Hypertens, 2012, 30(1): e29.

[14] 申小国, 郭银燕. 丹参酮ⅡA磺酸钠治疗冠心病心绞痛患者疗效观察[J]. 中国民康医学, 2016, 28(09): 68-70.

[15] 范学民, 卢小燕. 丹参酮ⅡA磺酸钠对慢性心力衰竭患者冠状动脉血流动力学的影响[J]. 北方药学, 2013, 10(09): 65.

[16] Zhang Hai-yan, Long Ming-zhi, Wu Zhi-wen, et al. Sodium tanshinone IIA silate as an add-on therapy in patients with unstable angina pectoris[J]. J Thorac Dis, 2014, 6(12): 1794-1799.

[17] Shang Qing-hua, Wang Han-jay, Li Si-ming, et al. The effect of sodium tanshinone IIA sulfate and simvastatin on elevated serum levels of inflammatory markers in patients with coronary heart disease: a study protocol for a randomized controlled trial[J]. Evid Based Complement Alternat Med, 2013, 2013(7404): 756519.

[18] Li Yong-sheng, Yang Yu-ping, Yu Dan, et al. The effect of Tanshinone IIA upon the TGF-beta1/Smads signaling pathway in hypertrophic myocardium of hypertensive rats[J]. J Huazhong Univ Sci Technolog Med Sci, 2009, 29(4): 476-480.

[19] Pang Hui, Han Bing, Yu Tao, et al. The complex regulation of tanshinone IIA in rats with hypertension-induced left ventricular hypertrophy[J]. PLoS One, 2014, 9(3): e92216.

[20] Jiang FL, Leo S, Wang XG, et al. Effect of tanshinone IIA on cardiomyocyte hypertrophy and apoptosis in spontaneously hypertensive rats[J]. Exp Ther Med, 2013, 6(6): 1517-1521.

[21] Feng Jun, Li Shu-sheng, Chen Hua-wen. Tanshinone IIA inhibits myocardial remodeling induced by pressure overload via suppressing oxidative stress and inflammation: possible role of silent information regulator 1[J]. Eur J Pharmacol, 2016, 791: 632-639.

[22] Tan Xue-ying, Li Jian-ping, Wang Xin-yue, et al. Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/nfatc3 pathway[J]. Int J Biol Sci, 2011, 7(3): 383-389.

[23] Yueh-shan Weng, Hsueh-fang Wang, Pai Pei-ying et al. Tanshinone IIA revents leu27IGF-II-induced cardiomyocyte hypertrophy mediated by estrogen receptor and subsequent Akt activation[J]. Am J Chin Med, 2015, 43(8): 1567-1591.

[24] 周倩. 丹参酮IIA对急性心肌缺血室性心律失常的影响[D]. 武汉：华中科技大学, 2013.

[25] Shan Hong-li, Li Xue-lian, Pan Zhen-wei, et al. Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1[J]. Br J Pharmacol, 2009, 158(5): 1227-1235.

[26] He Zhi-feng, Sun Chang-zheng, Xu Yi, et al. Reduction of atrial fibrillation by tanshinone IIA in chronic heart failure[J]. Biomed Pharmacother, 2016, 84: 1760-1767.

[27] Derek J Hausenloy, Derek M Yellon. Myocardial ischemia-reperfusion injury: a neglected therapeutic target[J]. J Clin Invest, 2013, 123(1): 92-100.

[28] Li Qiang, Shen Li, Wang Zhen, et al. Tanshinone IIA protects against myocardial ischemia reperfusion injury by activating the PI3K/Akt/mTOR signaling pathway[J]. Biomed Pharmacother, 2016, 84: 106-114.

[29] Hu Hui-lin, Zhai Chang-lin, Qian Ggang, et al. Protective effects of tanshinone IIA on myocardial ischemia reperfusion injury by reducing oxidative stress, HMGB1 expression, and inflammatory reaction[J]. Pharm Biol, 2015, 53(12): 1752-1758.

[30] Yuan Xun, Jing Son-bo, Wu Ling-zhen, et al. Pharmacological postconditioning with tanshinone IIA attenuates myocardial ischemia-reperfusion injury in rats by activating the phosphatidylinositol 3-kinase pathway[J]. Exp Ther Med, 2014, 8(3): 973-977.

[31] Li Yu-jie, Guo Yan, Chen Ying, et al. Establishment of an interleukin-1β-induced inflammation-activated endothelial cell-smooth muscle cell-mononuclear cell co-culture model and evaluation of the anti-inflammatory effects of tanshinone IIA on atherosclerosis[J]. Mol Med Rep, 2015, 12(2): 1665.

[32] Fan Guan-wei, Gao Xiu-mei, Wang Hong, et al. The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS[J]. J Steroid Biochem Mol Biol, 2009, 113(3-5): 275-280.

[33] Christian Stumpf, Fan Quiao-ling, Christian Hintermann, et al. Anti-inflammatory effects of danshen on human vascular endothelial cells in culture[J]. Am J Chin Med, 2013, 41(5): 1065-1077.

[34] Ren Z H, Tong Y H, Xu W, et al. Tanshinone IIA attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression[J]. Phytomedicine, 2010, 17(3-4): 212.

[35] Liang Z, Mao SJ, Yin ZN, et al. Preparation and quality evaluation of intravenous tanshinone IIA emulsion[J]. Chin J Chin Mater Med, 2008, 33(11): 1249-1252.

[36] 王高森. 丹参酮ⅡA微乳的研制及其质量评价[D]. 成都：四川大学, 2007.

[37] Lu Xiu-xia, He Lin, Deng Xi-long, et al. Preparation and quality evaluation of tanshinone IIA microemulsion for parenteral injection[J]. Chin Med Mat, 2014, 37(11): 2070-2076.

[38] 瞿继兰, 刘志东, 郭秀君, 等. 丹参酮ⅡA固体脂质纳米粒的制备及质量评价[J]. 天津中医药, 2014, 31(09): 564-566.

[39] Zhang Wen-li, Liu Jian-ping, Liu Xiao-xu, et al. Stealth tanshinone IIA-loaded solid lipid nanoparticles: effects of poloxamer 188 coating on in vitro phagocytosis and in vivo pharmacokinetics in rats[J]. Acta Pharm Sin B, 2009; 44(12): 1421-1428

[40] Wang Xiao-pan, Li Li, Huo Wei, et al. Characterization and stability of tanshinone IIA solid dispersions with hydroxyapatite[J]. Materials, 2013, 6(3): 805-816.

[41] Yan Hong-mei, Zhang Zhen-hai, Jiang Yan-rong, et al. An attempt to stabilize tanshinone IIA solid dispersion by the use of ternary systems with nano-CaCO3 and poloxamer 188[J]. Pharmacogn Mag, 2014, 10(2): 311-317.

[42] Zhao Xia, Liu Xin, Gan Li-she, et al. Preparation and physicochemical characterizations of tanshinone IIA solid dispersion[J]. Arch Pharm Res, 2011, 34(6): 949-959.

[43] Yan Hong-xiang, Li Jin, Li Zheng-hua, et al. Tanshinone IIA - loaded pellets developed for angina chronotherapy: deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation[J]. Eur J Pharm Sci, 2015, 76: 156-164.

丹参酮ⅡA对心血管系统的药理作用及剂型研究进展

Research Progress on Pharmacological Action and Dosage Form of Tanshinone II A on Cardiovascular System

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

[1]	张楠，张丹参. 蛇床子素抗癌作用及其剂型研究进展[J]. 神经药理学报, 2017, 7(6): 22-29.
[2]	任婧，张丹参. 姜黄素纳米剂型及在神经系统疾病中应用的研究进展[J]. 神经药理学报, 2017, 7(5): 45-51.
[3]	XIA Zhi, ZHANG Ying-mei, REN Jun. Endoplasmic Reticulum Stress and Metabolic Syndrome: Mechanisms and Therapeutic Potential / 内质网应激与代谢综合征的机制及治疗潜能[J]. 神经药理学报, 2012, 2(1): 33-44.